False‐positive urine screen test for MDMA in a patient exposed to mebeverine

  title={False‐positive urine screen test for MDMA in a patient exposed to mebeverine},
  author={Francesca Bedussi and Elisabetta Acerbis and Roberta Noseda and Davide Demagistri and Emanuela Zamprogno and Alessandro Ceschi},
  journal={British Journal of Clinical Pharmacology},
We would like to report the case of an 87-year-old female with falsepositive rapid toxicological screening test for ecstasy/methylenedioxymethamphetamine (MDMA). The patient was brought to the emergency department (ED) after being found in her room with a depressed level of consciousness. Physical examination revealed a Glasgow Coma Scale score of 10–11. A urine drug test was requested, and the results came back positive for benzodiazepines, opioids and ecstasy/MDMA. The family doctor confirmed… 
1 Citations


A potentially catastrophic outcome from a false-positive urinary drug screen immunoassay
  • R. Sheldon
  • Medicine
    The Journal of Forensic Psychiatry & Psychology
  • 2018
Clinicians must be mindful that urinary drug screens are not diagnostic, but also that not being believed can be devastating, especially for long-stay forensic inpatients.
A Cross-Reactivity of Fenofibric Acid With MDMA DRI Assay.
Fenofibrate's interference with MDMA immunoassay was confirmed and physicians had to be alerted that this treatment could lead to false-positive results.
False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology.
False positive results in amphetamines and MDMA immunoassays are possible in the presence of metoprolol, and toxicologists should be aware of frequent analytical interferences with immunoASSays.
False-positive interferences of common urine drug screen immunoassays: a review.
False-positive results support the generally accepted practice that immunoassay positive results are considered presumptive until confirmed by a second independent chemical technique.
Investigative implications of the instability and metabolism of mebeverine.
The anti-spasmodic drug mebeverine is used in the treatment of irritable bowel syndrome and is a precursor for a number of amphetamine-like compounds, which can produce false-positive amphetamine immunoassay results.
The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS.
It is shown that intake of MB leads to positive FPIA results for amphetamine, and the N-dehydroxybutyl metabolites of MB, MO-EA, HO-EA and the bis-dealkyl metabolite PMA should be responsible for the positive immunoassay results.
On the metabolism of the amphetamine-derived antispasmodic drug mebeverine: gas chromatography-mass spectrometry studies on rat liver microsomes and on human urine.
Gas chromatography-mass spectrometry studies of the metabolism of the antispasmodic drug mebeverine found the metabolites containing alcoholic or phenolic hydroxy groups were partly excreted into urine as conjugates, which are substances of forensic interest.